The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon. Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses, including vaccinia, cowpox, ectromelia, rabbitpox, monkeypox, and Variola (smallpox) virus.
Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. Tecovirimat was later approved by Health Canada in December 2021, followed by the approval from the European Commission in January 2022. Other than smallpox, tecovirimat is also indicated to treat complications due to replication of the vaccinia virus following vaccination against smallpox, and to treat monkeypox and cowpox in adults and children. Tecovirimat is available as both oral and intravenous formulations.
Tecovirimat is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. The efficacy of tecovirimat may be reduced in immunocompromised patients. In Europe, it is also indicated to treat complications due to replication of the vaccinia virus following vaccination against smallpox.
In Europe, tecovirimat is also used to treat monkeypox and cowpox in adults and children.
Pr Alexandra Calmy, Geneva, Switzerland
Fundación Huésped, Ciudad Autonoma de Buenos Aires, Argentina
Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
St. Michael's Hospital, Toronto, Ontario, Canada
St. Paul's Hospital, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
Toronto General Hospital, Toronto, Ontario, Canada
Midwest Clinical Research Center, Dayton, Ohio, United States
Coastal Carolina Research Center, North Charleston, South Carolina, United States
Meridian Clinical Research, Omaha, Nebraska, United States
Meridian Clinical Research, Omaha, Nebraska, United States
Aventiv Research Inc, Columbus, Ohio, United States
PPD Phase I Clinic, Austin, Texas, United States
PPD Phase I Clinic, Austin, Texas, United States
Paradigm Research, San Diego, California, United States
Sundance Clinical Research LLC, Saint Louis, Missouri, United States
Center for Pharmaceutical Research, Kansas City, Missouri, United States
Orlando Clinical Research, Orlando, Florida, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.